This short review outlines our understanding of cervical cancer precursors, concentrating on
the central etiologic role of persistent human papillomavirus infection. The stages of cervical …

Persistent high‐risk human papillomavirus (HR‐HPV) infection is the strongest risk factor for
high‐grade cervical precancer. We performed a systematic review and meta‐analysis of …

ABSTRACT A group of 47 experts representing 23 professional societies, national and
international health organizations, and federal agencies met in Bethesda, MD, September …

Background Pap cytology is known to be more specific but less sensitive than testing for
human papillomavirus (HPV) for the detection of high-grade cervical intraepithelial …

OBJECTIVE: The objective of the study was to compare 9 cervical cancer screening
strategies to the current screening standard (cytology with human papillomavirus [HPV] …

Objective Current US guidelines for cotesting recommend that the large numbers of women
who test Pap-negative, but human papillomavirus (HPV)–positive, return in 1 year, and …

Objective Declines in cervical cancer incidence and mortality in Canada and in the United
States have been widely attributed to the introduction of the Papanicolaou (Pap) test. This …

Background Several serological assays have been developed to detect antibodies elicited
against infections with oncogenic human papillomavirus (HPV) type 16. The association …

Abstract In 2006/2007, two vaccines were licensed against two of the most common HPV
types that cause about 70% of cervical cancers. Clinical trials show that vaccinated …

Human papillomavirus (HPV) is a well-studied etiologic agent for cervical cancer dysplasia
and neoplasia. HPV E6 and E7 viral proteins drive oncogenesis by blocking the activity of …